Phosphoinositide-3 Kinase Inhibitors

Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity.

Also Known As:

Inhibitor, Phosphoinositide-3 Kinase; Inhibitors, Phosphoinositide-3 Kinase; Kinase Inhibitor, Phosphoinositide-3; Kinase Inhibitors, Phosphoinositide-3; Phosphoinositide 3 Kinase Inhibitor; Phosphoinositide 3 Kinase Inhibitors; Phosphoinositide-3 Kinase Inhibitor

Networked: 10 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Phosphoinositide-3 Kinase Inhibitors: 10

Experts

1.	Huang, Yueting: 1 article (08/2022)
2.	Lin, Zhijuan: 1 article (08/2022)
3.	Shan, Weihang: 1 article (08/2022)
4.	Wu, Guixiang: 1 article (08/2022)
5.	Xia, Weilin: 1 article (08/2022)
6.	Xu, Bing: 1 article (08/2022)
7.	Zeng, Hanyan: 1 article (08/2022)
8.	Mascarenhas, John O: 1 article (01/2022)
9.	Qualls, David: 1 article (01/2022)
10.	Salles, Gilles: 1 article (01/2022)

Related Diseases

1.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2022 - "To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). "
2.	Lymphoma (Lymphomas) 08/01/2022 - "Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis."
3.	Neoplasms (Cancer) 02/28/2023 - "New 1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-2-phenylisoquinoline-1(2H)-ones as Phosphoinositide 3-kinase Inhibitors for Treating Cancer and other Diseases." 08/01/2005 - "Exposure of mesothelioma cell lines to LY294002, a phosphoinositide-3 kinase inhibitor, results in apoptotic cell death and decreased phosphorylated Akt in vitro and tumor burden reduction in vivo. "
4.	Hematologic Neoplasms (Hematological Malignancy) 01/05/2019 - "Idelalisib acts as a phosphoinositide 3 kinase inhibitor, which has been approved by the US FDA for the treatment of certain hematological malignancies. "
5.	Lamellar Ichthyosis (Harlequin Ichthyosis) 01/01/2020 - "It also includes hyperkeratotic reactions that have been more recently described with newly approved targeted therapies or immune checkpoint inhibitors, such as keratosis pilaris-like exanthema with second-generation BCR-ABL inhibitors, lamellar ichthyosis-like lesions with ponatinib, pityriasis rubra pilaris with the newly approved selective phosphoinositide 3 kinase inhibitor idelalisib, or psoriasis with anti-programmed death-1 and programmed death ligand-1."

Related Drugs and Biologics

1.	Telomerase (Telomerase Reverse Transcriptase)
2.	ruxolitinib
3.	navitoclax
4.	imetelstat
5.	parsaclisib
6.	Protein Isoforms (Isoforms)
7.	idelalisib
8.	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
9.	Small Interfering RNA (siRNA)
10.	Integrins

Related Therapies and Procedures

1.	Therapeutics
2.	Radioimmunotherapy
3.	Radiotherapy